The t(14;18) is the most frequent chromosomal aberration observed in follicular non-Hodgkin's lymphoma (NHL), and less frequently in diffuse large cell lymphoma (DLCL). The t(14;18) does not affect overall survival in follicular NHL or DLCL. It provides a unique lymphoma-specific marker that can be used to quantify residual disease during treatment, and may forward evaluation of new treatment protocols. The t(14;18) results in the deregulation of bcl-2, a proto-oncogene that protects against induction of programmed cell death (PCD). Nowadays, a whole family of bcl-2-related genes has been identified and consist of members which can either protect or promote induction of PCD. The family members form protein dimers, and the relative abundance of specific dimers regulates the cellular sensitivity to death signals (the rheostat model). Aberrant expression of different family members in several types of malignancies alter the cellular rheostat and thereby promote cellular resistance to chemotherapy.
t(14;18) and non-Hodgkin's lymphoma
Specific chromosomal abnormalities are associated with certain types of malignancies. In follicular non-Hodgkin's lymphoma (NHL), a specific chromosomal translocation involving chromosome 14 and 18, the t(14;18)(q32;q21), is present in about 60% of cases (Table 1A ). The t(14;18) has also been found in 16% of cases with de novo diffuse large cell NHL (DLCL) including immunoblastic (IB) NHL (Table 1B) . The incidence of t (14;18) in follicular NHL or DLCL may differ in the populations investigated. The incidence of t (14;18) in follicular NHL and DLCL, as determined by either cytogenetic analysis or molecular techniques such as Southern blot or polymerase chain reaction (PCR), is only 38 and 9% in the Japanese population vs 62 and 18% in the rest of the world for follicular NHL and DLCL respectively. [1] [2] [3] The t(14;18) involves the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 and the B cell leukemia/lymphoma-2 (bcl-2) gene on chromosome 18q21 (Figure 1 ). During the translocation event, the tip of chromosome 18 including the coding region of bcl-2 is coupled to one of the IgH joining gene segments (J H ) on chromosome 14. This aberrant chromosome 14 is cytogenetically denoted as the 14q + chromosome. In the reciprocal 18q − chromosome, the tip of chromosome 14 including the IgH variable (V H ) and diversity (D H ) gene segments is coupled to the shortened chromosome 18, downstream of the bcl-2 gene. The chromosomal breakpoints on chromosome 18 are clustered in two regions: a 150 bp region in the 3′ untranslated region of bcl-2 which is called the major breakpoint region (MBR) and a 500 bp region 20 kilobases downstream of bcl-2 which is called the minor cluster region (MCR). [4] [5] [6] In t(14;18) positive follicular NHLs, about 79% of the breakpoints on chromosome 18 occur within the MBR and about 21% occur in the MCR (Table 1A) .
Detection of chromosomal abnormalities by karyotypic analysis or molecular biological techniques such as Southern blot or PCR ( Figure 2 ) are useful tools for detecting t(14;18) in tumor biopsies which contain a high percentage of malignant cells. Cytogenetic analysis or molecular analysis both detect t (14;18) in about an equal number of cases in follicular NHL (Table 1A) and DLCL (Table 1B) . The PCR technology provides a unique advantage in that it is extremely sensitive in comparison to karyotypic analysis or Southern blot. 7 The PCR technique may detect a single t (14;18) , reflecting a single lymphoma cell, in a background of about one hundred thousand normal cells. 8, 9 By PCR, it now becomes possible to monitor consecutive patient blood and bone marrow samples for minimal residual disease during treatment.
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Variant translocations involving bcl-2
A number of translocations involving bcl-2 but different from the classical t(14;18) have been observed in cases with follicular NHL and a case with lymphoblastic lymphoma. In these cases, translocation breakpoints have been found in a 1.5 kb region upstream and within the first exon of bcl-2. This region has been denoted VCR, for variant cluster region. In one case, the breakpoint was mapped about 10 kb upstream of the bcl-2 locus within another transcriptionally active locus which is called follicular variant translocation gene (fvt-1). 13 The IgH J H 6 region was coupled to bcl-2 in one case, 14 but in most cases the kappa or lambda immunoglobulin light chain genes (IgL) are juxtaposed to bcl-2 in a head-to-head orientation, resulting in the t(2;18)(p11;q21) or the t(18;22) (q21;q11). 2, 15, 16 Based upon molecular analysis using Southern blot, the t(2;18) and t(18;22) have been associated only recently with B cell chronic lymphocytic leukemia (B-CLL), and seem to occur in about 5% of cases ( USA  4/9  -----130  USA  29/48  -----131, 132  USA  14/20  -----133  World  37/64  -----134  USA  -9/18  2/18  12/18   a   --5 6  USA  -21/36  11/36  32/36  --135  USA  -11/17  ----136  USA  10/13  21/31  ----137  USA  -11/37  ---- USA  7/29  -----131, 132  World  9/78  -----134  USA  7/32  -----133  USA  2/13  8/20  ----137  USA  -3/30  1/30  5/30  --135  USA  -4/26  ----136  USA  -5/31  ----138  USA  -NS  NS  10/54   a   --2 rearrangement process 19 and even the V H to D H -J H rearrangement process. 20 Tsujimoto et al 21 + chromosomal junction of six follicular NHL patients in a 2% agarose gel. Lane M: X-174 HaeIII marker: marker bands of 872 bps, 603 bps, 310 bps and 281/271 bps are shown. Lanes 1-6: PCR products from six follicular NHL patients. All six patients had a chromosomal breakpoint within the MBR of the bcl-2 gene. For patient 1, 3-6 bcl-2 was rearranged to the IgH JH6 gene segment. For patient 2, bcl-2 was rearranged to the IgH JH4 gene segment. The bcl-2-JH4-JH5 PCR product of patient 2 is also visible.
The clinical significance of t(14;18) in NHL
Chromosomal aberrations involving chromosome 2, 7 or 17 or chromosomal breaks in 1p32-36, 1q21-23, 6q21-25 are prognostic factors in follicular NHL or DLCL which are associated with decreased overall survival. [24] [25] [26] The accumulation of several genetic hits during NHL progression leads to a further reduction of overall survival, 24, 26 probably due to dedifferentiation to a higher malignant state. In one initial study involving 20 follicular NHL patients, a correlation was found between the presence of the t(14;18) and decreased overall survival. No such effect was found in many other studies involving follicular NHL or DLCL patients. [26] [27] [28] [29] [30] The t(14;18) has been correlated in several studies with a lower incidence of complete remission after chemotherapy and decreased disease-free survival in follicular NHL and DLCL. 25, 27, 31, 32 Since overall survival is not affected, these results indicate that relapses are responsive to further treatment. Paradoxically, one study correlated the identification of t(14;18) in DLCL at time of relapse with increased overall survival. 26 The chromosomal breakpoints in the t(14;18) cluster in small regions. The PCR is therefore an excellent method for easy, fast and extremely sensitive detection of residual lymphoma cells within blood or bone marrow samples of follicular NHL patients, 8, 9, 19 and has been applied in several experimental as well as clinical studies. 7, 33, 34 Although t(14;18)s have been found at very low frequency in benign hyperplastic lymph nodes and blood samples of normal blood donors (see section 2.3 [35] [36] [37] ), the exact molecular composition of each t(14;18) is unique and can therefore be used as lymphomaspecific marker in t(14;18)-positive follicular NHL patients. Monitoring of residual t(14;18) carrying lymphoma cells by PCR in bone marrow samples of patients who are in clinical complete remission and who had been pretreated with highdose chemotherapy followed by ABMT, proved very useful for identifying patients with increased risk of relapse. Patients with residual lymphoma cells in the autograft after extensive immuno-purging had a significantly reduced disease-free survival when compared to patients in whom no residual lymphoma cells could be detected (P Ͻ 0.00001). None of 58 patients without disease in bone marrow samples after ABMT relapsed during a median follow-up of about 2 years. 31, 32 In contrast, disease-free survival for 35 patients with apparent disease after ABMT was only 15 months. No lymphoma cells were detected in consecutive blood samples after transplantation in patients who had been transplanted with autologous marrow without evidence of residual disease. Thirteen out of 14 patients who had been transplanted with autologous marrow with PCR-detectable disease remained positive after transplantation. 31, 32 Qualitative screening for residual t(14;18)-positive lymphoma cells seems, therefore, sufficient to identify patients with increased risk for relapse. However, residual t(14;18)-positive lymphoma cells may remain detectable at low levels in follicular NHL patients who are in stable clinical remission. 38 So, qualitative screening may be insufficient for predicting relapse. Accurate quantitative screening in consecutive samples may be a prerequisite in order to predict progression or reoccurrence of disease. [10] [11] [12] Until recently, no curative treatment options were available for patients with follicular NHL. Now, new treatment protocols are emerging based upon high-dose chemotherapy with autologous stem cell support, allogeneic stem cell transplantation, new purine analogues, interferon alpha or monoclonal antibodies. Quantitative monitoring of t(14;18) carrying cells may have a major clinical impact on future evaluations of these treatment protocols.
bcl-2, a new type of oncogene
The bcl-2 gene is involved as an early genetic hit in the oncogenesis of the t(14;18)-positive follicular NHL. It spans more than 230 kb of DNA, 39 and consists of three exons of which exon 2 and a small part of exon 3 encode for protein ( Figure 1A ). Exons 2 and 3 are separated by a large intron of about 225 kb. The MBR is located in the untranslated region of exon 3, 40 and therefore, the protein coding domain is maintained during the t(14;18). Dependent on splicing of intron 2, bcl-2 encodes for two different mRNAs, Bcl-2␣ and Bcl-2␤ 41 of which only Bcl-2␣ seems to have biological relevance. The BCL2 protein is a membrane protein and is located at the cytosolic site of the nuclear envelope, the endoplasmatic reticulum and the outer mitochondrial membrane probably near mitochondrial contact zones. 42, 43 Bcl-2 is unique among proto-oncogenes, and it does not promote proliferation like cmyc, nor contributes to tumorigenesis upon loss-of-function like p53 or retinoblastoma (pRB), but it prevents induction of cell death under cytotoxic conditions. 44 The bcl-2 gene is able to prevent apoptosis induced by diverse cytotoxic conditions in various cell types ranging from growth factor deprivation, generation of intracellular reactive oxygen radicals, hypoxic conditions, many different chemotherapeutic agents and expression of cellular genes under suboptimal conditions (Table 3) . Bcl-2 can also protect against some forms of necrotic cell death. 45, 46 The BCL2 protein is expressed in many different tissues. BCL2 is expressed in early hematopoietic progenitor cells of all lineages. BCL2 is also present in mature T lymphocytes which reside in the thymic medulla, as well as in the longlived IgM/IgD memory B cells in the germinal center follicle mantle zone of secondary lymphoid tissue. BCL2 is also present in the stem cells of differentiating epithelium like skin and intestine, in epithelial cells of hormonal responsive tissue like breast epithelium, thyroid gland epithelium, basal cells of prostate epithelium and acinar cells of pancreatic epithelium as well in neurons that are long-lived post-mitotic cells. 47, 48 Bcl-2 knock-out mice have helped in determining the function of bcl-2. These mice seem to have a normal embryonic development, but soon after birth they become retarded in growth, loose pigmentation during the second hair follicle Table 3 bcl-2 inhibits induction of cell death by various cytotoxic stimuli cycle, and acquire defects in the small intestine. These mice ultimately die of renal failure due to severe polycystic kidney disease. [49] [50] [51] B and T cell numbers are initially normal and both cell types demonstrate normal proliferative responses. Massive cell death occurs in the lymphoid compartment soon after birth and results in lymphocytopenia. 49, 50 Although bcl-2 seems not to be absolutely required for embryonal development, it is essential for long-term survival and maintenance of at least some cell types. Bcl-2 mRNA is expressed in most pro-B cells and in mature naive B cells, but it is temporarily down-regulated in the pre-B cell stage. 52 In contrast, the bcl-2 homologous gene bcl-xl becomes up-regulated during the pre-B cell stage. 53 Downand up-regulation of Bcl-2 and Bcl-xl may coincide with several selection processes. First, selection for functional rearrangements of IgH and IgL loci may coincide with downregulation of Bcl-2 and up-regulation of Bcl-xl. Second, negative selection for recognition of self-antigen may coincide with down-regulation of Bcl-xl and up-regulation of Bcl-2. Third, positive selection of centrocytes which express abundant Bcl-2 mRNA but no protein. 48, 54 In vitro stimuli like ␣IgM, ␣CD23 plus rIL-1␣, ␣CD40 or CD40-ligand, which mimic in vitro selection stimuli induce BCL2 and BCL-X L up-regulation in centrocytes of splenic B cells. 
Bcl-2 expression during B cell development

t(14;18) deregulates bcl-2 gene expression
Due to the t(14;18),the bcl-2 gene is in close proximity to the IgH enhancer. This results in a continuous high expression of the bcl-2 gene 40, [56] [57] [58] (Table 1A) . Remarkably, the number of follicular NHL cases expressing BCL2 protein (about 90%) far exceeds the number of cases with detectable t(14;18) (about 60%). Only 54% of the cases expressing abundant BCL2 protein have detectable bcl-2 rearrangements. Since only some of these cases with t(14;18) may have remained undetectable by cytogenetic analysis or molecular analysis due to alternative breakpoints in the bcl-2 locus, and since normal germinal center B cells do not express BCL2 protein, 47, 48 it is apparent that additional mechanisms exist which results in a deregulated bcl-2 gene expression.
A similar discordance between BCL2 protein expression and the presence of translocations involving bcl-2 exists for DLCL and B-CLL. About 70% of DLCL cases express abundant BCL2,but only 21% of BCL2-positive cases have a rearranged bcl-2 gene (Table 1B) . Virtually all B-CLL cases express abundant BCL2 protein (Table 2 ). In 70% of these cases, expression of BCL2 is equivalent or even higher compared to the BCL2 expression of a t(14;18) carrying follicular NHL cell line. 59 Since only 5% of B-CLL cases have a bcl-2 gene rearrangement, it is unclear if high BCL2 protein expression is of pathological origin. B-CLL is supposed to be the malignant counterpart of normal mantle zone B cells, and high BCL2 protein expression in B-CLL could therefore be a mere reflection of long-lived memory B cell origin.
Since most cases of follicular NHL have a t(14;18) (Table 1A ) and since enforced bcl-2 expression in transgenic mice seems oncogenic, 60 it seems logical that deregulated bcl-2 expression is an important early step in the pathogenesis of follicular lymphoma. Similar translocations are also found in benign hyperplastic lymph nodes 35 and blood samples of healthy blood donors at very low frequency for up to several years, 36, 37 and indicates that neoplastic development requires additional genetic hits. The nature of these genetic defects and the developmental stage in which they become apparent remains elusive. Antigen specificity and selection processes may play an important role in the pathogenesis of follicular NHL. Follicular NHL cells are frozen in the centroblastic/centrocytic differentiation stage in which the somatic mutation machinery remains active. [61] [62] [63] [64] The somatic mutation profiles of follicular NHL cells provide evidence that these neoplastic cells remain under continuous affinity selection, 65 ,66 so antigen-driven proliferation processes are most likely involved in the maintenance of the malignant cell population. 20 Bcl-2 transgenic mice are excellent tools to demonstrate the tumorigenicity of deregulated bcl-2 gene expression. In these mice, non-cycling polyclonal follicular center B cells accumulate, resulting in large splenic and nodular follicular center areas. B cell maturation is not inhibited and immunoblasts and plasma cells are present. Splenic B cells have a prolonged lifespan, but in vitro activation seems unaffected. 67, 68 Another Bcl-2 transgenic mice model demonstrates increased B cell numbers of all developmental stages without evidence of follicular hyperplasia, 69 and probably reflects differences in the genetic background or bcl-2 expression cassette in both transgenic lines. Bcl-2 overexpression in the B cell lineage prolongs antibody responses upon antigenic challenge, 69 and prolongs B cell memory. 70 After a relatively long latency period, 11% of these mice develop monoclonal high-grade diffuse large cell immunoblastic lymphoma. 60 This clearly demonstrates that t(14;18)s may occasionally occur in every individual, but these cells disappear over time or are specifically eliminated by the immune system. 36, 37 In some unfortunate cases, however, these cells acquire secondary genetic defects which enable these cells to escape from immune surveillance and to exploit their neoplastic appearance fully resulting in follicular NHL.
The bcl-2 gene family
Many different evolutionary conserved proteins have been discovered which are homologous to BCL2 and are recognized as the bcl-2 gene family. Family members share at least two regions of homology with BCL2 and are called BCL2 homology domains 1 and 2 (BH1, BH2). Some family members like bcl-x, 71 bcl-w, 72 mcl-1, 73, 74 a1/bfl-1 [75] [76] [77] and nr-13 78, 79 provide protection against cell death-inducing stimuli. Other family members like bax, 80 bak, 81-83 bad 84 and bcl-xs 71 have an opposite effect and promote cell death.
Bcl-2 family members form protein dimers, 80, 85, 86 and the formation of specific dimers functions as a cellular rheostat to determine the cellular fate following cell death signals. 87 In this rheostat model, relative abundance of cell death promoters like BAX would favor BAX homodimer formation and thereby promote cell death. Relative abundance of survival proteins like BCL2 would favor formation of BCL2/BAX heterodimers or BCL2 homodimers and thereby prevent induction of cell death. Factors like BAD and BCL-X s compete for binding to cell death inhibiting molecules like BCL-X L or BCL2, thereby displacing BAX and facilitating BAX homodimerization and induction of cell death 71, 84 ( Figure 3 ).
Figure 3
The rheostat model according to Oltvai et al. 
BCL2 homology domains involved in regulation of apoptosis
Protein alignment of several family members revealed at least four domains of homology, and are denoted BH1 to BH4 (Figure 4 ). These domains are involved in protein dimerization
Figure 4
Conservation of protein domains among bcl-2 gene family members. (a) Protein domains BH1-4 are conserved in family members with anti-apoptotic activity, whereas only BH1-3 are conserved in members with pro-apoptotic activity. (b) alignment of homology domains (grey boxed residues) among different family members. Conserved amino acid residues are shown in bold capitals. Large arrows refer to amino acid residues in BH3 of BAK which interact with residues (small arrows) in the hydrophobic pocket (BH1-3) of BCL-XL. 101 and cell death regulation, although the contribution of the domains is different within different family members. BH1 to BH3 are conserved in all family members except BAD, whereas BH4 is only conserved in family members with antiapoptotic activity. BH1 and BH2 are critical for the cell death protecting function of BCL2 and BCL-X L . Specific amino acid substitutions in BH1 and BH2 result in loss of anti-apoptotic activity as well as loss of binding to BAX. Mutant nonfunctional BCL2 still dimerizes with wild-type BCL2, suggesting that BCL2 and BCL-X L must dimerize with BAX to display their anti-apoptotic activity. 85, 88 However, the amino acid residues within BH1 and BH2 that are involved in maintaining the antiapoptotic activity of BCL2 and BCL-X L are partially different. Moreover, the cell death protective function of BCL-X L has been demonstrated in the absence of heterodimerization with BAX or BAK. 89 The BH3 domain seems to be crucial for pro-apoptotic molecules such as BAK and BAX. In BAK, BH3 is sufficient for promoting death as well as dimerization with BCL-X L . 90 BAX homodimerization has been demonstrated to occur by BH3 to BH3 interaction. 91 Deletion of BH3 renders both BAX and BAK non-functional. 90, 91 Moreover, a BH3 homologous domain has also been identified in pro-apoptotic molecules BIK/NBK, 92,93 BID 94 and HRK, 95 which are distantly related to the bcl-2 gene family. Therefore, BH3 may encode a new critical death domain. Consistent with this, BCL2 can be converted into a pro-apoptotic molecule upon exchange of the BH3 domain with the equivalent domain of BAX. 96 Although the BH3 seems to be sufficient for homodimerization of BAX and for dimerization of BAX or BAK with BCL-X L , BCL2 homodimerization may involve all four homology domains. BCL2 probably forms homodimers by interaction of the N-terminal portion of the protein which includes BH4 with the C-terminal portion of the BCL2 partner protein which includes BH3, BH1 and BH2. 86, 97 All four homology domains as well as the spacing between BH3, BH1 and BH2 are vital for cell death protective function. 98, 99 BH4 seems not to be involved in heterodimerization with BAX. 91, 97 Based upon studies using deletion mutants, the involvement of the homology domains in the formation of specific protein dimers may be different among family members, as summarized in Figure 5 .
The three dimensional structure of BCL-X L consists of two central hydrophobic ␣-helixes (␣5 and ␣6), that are flanked by five amphiphatic ␣-helixes. The three conserved domains BH1 (part of ␣4, ␣5), BH2 (part of ␣6, ␣7) and BH3 (␣2) are in close spatial proximity, and form a hydrophobic cleft. 100 Investigating the BAK-BCL-X L interaction, a synthetic peptide related to the BH3 region of BAK was able to bind in the hydrophobic cleft of BCL-X L . The interaction was mediated by hydrophobic and electrostatic interactions between specific residues of the BH3 region from BAK and residues from the hydrophobic cleft of BCL-X L . Furthermore, this peptide could inhibit the interaction between wild-type BAK and BCL-X L through competition. 101 These data are compatible with the model as proposed in Figure 5 , and the pro-apoptotic activity and protein interactions of BAK or BAX seem solely dependent on the BH3 domain. All four homology domains in BCL2 and BCL-X L are required for anti-apoptotic activity and participation in protein dimers, and are probably crucial for forming a hydrophobic cleft.
We recently found mutations in bax in about 21% of human malignant hematopoietic cell lines. 102, 103 Several cell lines contained a deletion of an insertion in an identical deoxyguanosine (G8) tract, resulting in truncation of BAX. Identical mutations have recently been described in about 50% of colorectal cancers of the microsatelite mutator phenotype. 104 Three different point mutations, G11E, G67R and G108V, were found in independent lines. BAX G67R and BAX G108V were tested for function, and demonstrated altered protein dimerization and loss of pro-apoptotic activity. As a consequence of the BAX G67R mutation, a positive charged Arginine residue is introduced in the hydrophobic site of the BH3 domain. Both neighboring residues, lle 66 and Asp
68
, are involved in the binding of BAK to BCL-X L . 101 The G67R mutation may interfere with interactions of these residues with the hydrophobic pocket of BCL2 or BCL-X L . Strikingly, this BAX mutant is indeed unable to form heterodimers with BCL-2 or BCL-X L , but can still form homodimers. 103 Although BH1 of BAK or BAX does not seem to be involved in pro-apoptotic function or protein interactions, 90 ,91 the BH1 BAX G108V mutation resulted in a non-functional protein that was unable to form homodimers, although heterodimerization seemed unaffected. Sattler et al 101 suggested that binding of BAK to BCL-X L necessitates a conformational change in BAK in order to expose the BH3 domain to the protein surface. The BAX G108V mutation may interfere with such a conformational change of BAX, at least for homodimerization. Whatever residues are involved in protein dimerization, both mutations demonstrate that hetero-and homodimerization of BAX may involve different amino acid residues of the BH3 domain. BH1 may directly be involved in protein interactions or is important for protein conformation.
Bcl-2 gene family and resistance to chemotherapy
Traditionally, it has been hypothesized that chemotherapeutic agents are effective in eliminating proliferating cells, but from emerging data it now becomes clear that at least some of these compounds function by inducing apoptosis. Many genes are involved in the regulation of cell death pathways, and mutations in these genes can contribute to cellular resistance to chemotherapeutic regimens and radiation. One of these genes is the tumor-suppressor gene p53. This is one of the most frequently mutated genes in human cancer. 105, 106 In experimental systems, p53 deficiency has been associated with reduced death under suboptimal growth conditions, 107 treatment with chemotherapeutic compounds or gamma-radiation. [108] [109] [110] [111] [112] Within hematopoietic malignancies, mutations in p53 have been associated with resistance to treatment and reduced survival in AML, MDS and B-CLL. 113, 114 The mechanism by which P53 induces apoptosis remains enigmatic, but recently bax has been identified to be up-regulated specifically by P53, 115, 116 and may participate in the p53-dependent death pathway. P53-induced apoptosis is reduced but not blocked in the absence of bax, 117, 118 indicating that bax participates in the p53-dependent death pathway but that other death effectors are involved as well. Furthermore, bax deficiency promotes cellular transformation indicating that bax can act as a tumor-suppressor gene as well. 117, 118 Reduced BAX levels and resistance to cisplatin-induced apoptosis may be related to absence of functional p53 in progressive ovarian carcinomas. 119 Decreased BAX expression correlates with poor prognosis and shortened overall survival in women with metastatic breast cancer, 120 but is not correlated with p53 status. 121 Enforced BAX expression in malignant breast cancer lines restores the sensitivity to serum deprivation and reduces tumorigenicity in scid mice. 121 The bcl-2 gene is one of the best studied family members in relation to resistance to chemotherapy. It protects against various cytotoxic compounds with different mechanisms of action (Table 3 ). BCL2 does not inhibit early effects of cytotoxic compounds such as suppression of proliferation or breaks in chromosomal DNA. Neither does it affect DNA repair. BCL2 inhibits the onset of a distal death pathway, leading to a reduction of apoptosis and the characteristic chromosomal DNA breakdown. [122] [123] [124] [125] Since DNA damage by cytotoxic drugs is not inhibited and cells continue to proliferate after drug removal, 123, 126, 127 BCL2 expression promotes selection of cells with additional genetic hits and therefore contributes to dedifferentiation of disease. BCL2 overexpression also indirectly promotes chemotherapy resistance by increasing the intracellular GSH levels, 46 and shifts the cellular redoxpotential to a more reduced state. High GSH levels detoxify a number of chemotherapeutic compounds by reducing freeradical intermediates. Similarly to BCL2, BCL-X L can protect against cell death induced by various chemotherapeutic compounds. 127, 128 However, the ineffectiveness of bcl-2 but not bcl-xl expression in repressing apoptosis in a murine B cell line suggests that both genes function in independent pathways. 129 
Concluding remarks
The proto-oncogene bcl-2 is involved in the pathogenesis of follicular NHL and probably in other diseases. Overexpression of BCL2 due to the t(14;18) in follicular NHL is not correlated with overall survival, but the t(14;18) provides at least a disease-specific marker which can be used for monitoring of residual disease. This may not only allow individualization of therapy, but may be especially helpful in determining the effectiveness of future treatment protocols. Bcl-2 represents a type of proto-oncogene that promotes cellular viability under circumstances which normally would lead to apoptosis. Nowadays, a whole family of bcl-2-related genes has been identified and consists of anti-apoptotic members like bcl-2 and pro-apoptotic members like bax. Proteins of this family form protein dimers. The viability of a cell is determined by the relative abundance of specific dimers as explained by the rheostat model. Aberrant expression or reduced expression of some family members contributes to cellular resistance towards chemotherapy. Although much is known about the influence of independent members on the outcome of chemotherapy, future research should be focused on the expression pattern of the entire family as a whole in relation to chemotherapy resistance. Furthermore, a better understanding of the involvement of different homology domains in the formation of specific dimers and outcome on cell survival may provide potential targets for the development of new therapeutic regimens.
